Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

2A Pharma ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.2%   Bankruptcy risk   5.9% 5.5% 4.0% 3.1% 29.6% 8.0% 15.7% 13.3%   Credit score (0-100)   41 43 50 55 1 30 12 17   Credit rating   BBB BBB BBB BBB C BB BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 -0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   947 1,525 2,096 1,948 -210 159 0.0 0.0   EBITDA   -56.6 -72.6 385 371 -1,507 -103 0.0 0.0   EBIT   -59.7 -80.9 377 362 -1,516 -109 0.0 0.0   Pre-tax profit (PTP)   -59.9 -81.4 376.9 353.2 -1,524.0 -108.7 0.0 0.0   Net earnings   -59.9 -81.4 322.4 271.7 -1,524.0 -42.6 0.0 0.0   Pre-tax profit without non-rec. items   -59.9 -81.4 377 353 -1,524 -109 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   27.8 30.2 21.9 13.6 5.2 0.0 0.0 0.0   Shareholders equity total   426 344 667 938 -586 672 406 406   Interest-bearing liabilities   0.0 0.0 0.0 0.0 80.2 0.0 0.0 0.0   Balance sheet total (assets)   559 626 1,055 1,323 1,309 834 406 406   Net Debt   -192 -112 -59.5 -557 -649 -433 -406 -406     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   947 1,525 2,096 1,948 -210 159 0.0 0.0   Gross profit growth   0.0% 61.1% 37.4% -7.1% 0.0% 0.0% -100.0% 0.0%   Employees   1 1 3 2 2 2 0 0   Employee growth %   0.0% 0.0% 200.0% -33.3% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   559 626 1,055 1,323 1,309 834 406 406   Balance sheet change%   0.0% 11.9% 68.6% 25.4% -1.1% -36.3% -51.4% 0.0%   Added value   -56.6 -72.6 385.4 370.7 -1,507.4 -103.5 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   25 -6 -17 -17 -17 290 -300 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -1.0 -2.0 1.0 2.0 -1.0 -2.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -6.3% -5.3% 18.0% 18.6% 721.4% -68.2% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -10.7% -13.7% 45.1% 30.5% -94.2% -8.0% 0.0% 0.0%   ROI %   -14.0% -21.0% 75.1% 45.3% -297.6% -28.9% 0.0% 0.0%   ROE %   -14.1% -21.1% 63.8% 33.9% -135.6% -4.3% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   76.1% 55.0% 63.2% 70.9% -30.9% 80.5% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   339.6% 153.7% -15.4% -150.3% 43.0% 418.6% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% -13.7% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 21.0% 0.1% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   3.9 2.0 2.6 3.3 0.7 3.2 0.0 0.0   Current Ratio   3.9 2.0 2.6 3.3 0.7 3.2 0.0 0.0   Cash and cash equivalent   192.1 111.6 59.5 557.0 728.7 433.1 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   389.0 287.4 618.2 898.2 -617.5 362.8 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -57 -73 128 185 -754 -52 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -57 -73 128 185 -754 -52 0 0   EBIT / employee   -60 -81 126 181 -758 -54 0 0   Net earnings / employee   -60 -81 107 136 -762 -21 0 0